Coronavirus information for Feinberg.

Skip to main content

Stroke & Neurocritical Care Trials

As part of an academic medical center, the Division of Stroke & Neurocritical Care at Northwestern University Feinberg School of Medicine aims to improve human health through scientific research. Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

The following searchable list includes all the stroke and neurocritical care clinical trials currently looking for participants.

Trials
cIRB: AtRial Cardiopathy and Antithrombotic Drugs In prevention After Crypotgenic Stroke
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of u…
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.
Inclusion Criteria:

  • Age ≥ 45 years.
  • Clinical diagnosis of ischemic stroke + brain imaging to rule out hemorrhagic stroke.
  • Modified Rankin Scale (MRS) score ≤ 4.
  • Ability to be randomized within 3 to 120 days after stroke onset.
  • ESUS (embolic stroke of underdetermined source).
Exclusion Criteria:

  • History of atrial fibrillation
  • Clear indication for treatment-dose anticoagulant therapy, such as venous thromboembolism or a mechanical heart valve.
  • Need for antiplatelet agent other than aspirin, such as clopidogrel after implantation of a coronary artery stent.
  • History of spontaneous intracranial hemorrhage.
  • Chronic kidney disease with serum creatinine ≥2.5 mg/dL.

Caprio, Fan ZhangCaprio, Fan Zhang
  • Map it 201 E. Huron St.
    Chicago, IL
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03192215 STU00206251
More Info
Copy
AtRial Cardiopathy and Antithrombotic Drugs In prevention After Crypotgenic Stroke- Cognition and Silent Infarcts
ARCADIA-CSI an ancillary study to the ARCADIA trial in which we will assess cognitive function and silent infarcts in a subset of the ARCADIA population. The purpose of ARCADIA-CSI i…
ARCADIA-CSI an ancillary study to the ARCADIA trial in which we will assess cognitive function and silent infarcts in a subset of the ARCADIA population. The purpose of ARCADIA-CSI is to determine the effect of apixaban vs aspirin on these two additional outcomes in patients with stroke of unknown cause and atrial cardiopathy.
Patients randomized in the ARCADIA trial and on study drug will be eligible for ARCADIA-CSI if they can undergo cognitive testing (english speaking) and have no MRI contraindications.
Caprio, Fan ZhangCaprio, Fan Zhang
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03192215 STU00211262
More Info
Copy
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2) (Protocol #: B01-04)
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem®, in adults who have suffered an acute ischemic stroke in the pre…
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem®, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.

Primary Inclusion Criteria:

  • Male or female subjects ≥18 years of age
  • Clinical diagnosis of ischemic stroke involving cerebral cortex
  • Onset of stroke symptoms must have occurred 18 to 36 hours prior to the planned start of administration of the investigational product
  • Occurrence of a moderate to moderately severe stroke with a persistent neurologic deficit documented by a NIHSS score of 8 to 20 (inclusive) that does not change by ≥4 points during the initial screening period
  • A mRS score of 0 or 1 prior to the onset of symptoms of the current stroke

Primary Exclusion Criteria:

  • Presence of a lacunar or a brainstem infarct
  • Comatose state
  • Brain hemorrhage
  • Major neurological event such as stroke or clinically significant head trauma within 6 months of enrollment into the study

Batra, AyushBatra, Ayush
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03545607 STU00209969
More Info
Copy